The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2024 | Recent advancements in BPDCN: diagnostic criteria, pathophysiology, and treatment
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses recent advancements in the field of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He mentions updates to the World Health Organization (WHO) diagnostic criteria, the evolution of BPDCN from pre-existing myeloid neoplasms, and the landscape of treatment for BPDCN. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Cimeio Therapeutics: Consultant; IDRx: Consultant; Jnana Therapeutics: Consultant; ProteinQure: Consultant; Qiagen: Consultant; Medzown: Stokeholder, SAB; AbbVie: Research Support; Stemline Therapeutics: Research Support.
